Evidence map›Paper›PMID 41350288›Full record

ArticleNature communications2025

LANA-specific CD4

Michelle Böni, Shitao Peng, Danusia Vanoaica, Kareem Haal, Svenja L Nopper, Lisa Rieble, Sandra Schmid, Alma Delia Valencia-Camargo, Angelika Holler, Hans Stauss and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michelle BöniViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-7829-258X
Shitao PengViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Danusia VanoaicaViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Kareem HaalViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0006-8868-1665
Svenja L NopperViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Lisa RiebleViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-9773-8607
Sandra SchmidViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Alma Delia Valencia-CamargoViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Angelika HollerInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, UK.
Hans StaussInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, UK.ORCID http://orcid.org/0000-0003-4340-7911
Christian MünzViral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. christian.muenz@uzh.ch.ORCID http://orcid.org/0000-0001-6419-1940

Funding

Krebsliga Schweiz (Ligue Suisse Contre le Cancer) KFS-5896-08-2023-RSchweizerische Multiple Sklerose Gesellschaft (Swiss Multiple Sclerosis Society) 2023-17Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030L_197952/1Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) CRSII_222718_10000065
6 · The paper itself

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) infection is linked with the development of life-threatening malignancies in elderly and immunocompromised hosts, suggesting tight control of the infection by T cell responses. T cells against KSHV, however, are barely detectable in infected individuals, and the mechanisms underlying immune recognition of KSHV-infected cells remain poorly understood. Here, we present publicly available sequences of T cell receptors (TCRs) targeting the KSHV latency-associated nuclear antigen (LANA/ORF73). By using these TCRs transgenically expressed on T cells as identifiers for KSHV-specific cells, we show that despite their failure to recognize KSHV-infected B cells in vitro, activated effector memory differentiated LANA-specific CD4

Indexed as

Antigens, ViralCD4-Positive T-LymphocytesHerpesviridae InfectionsHerpesvirus 8, HumanNuclear ProteinsSarcoma, KaposiAnimalsB-LymphocytesDisease Models, AnimalHumansMiceMice, TransgenicReceptors, Antigen, T-CellAntigens, Virallatency-associated nuclear antigenNuclear ProteinsReceptors, Antigen, T-Cell

Identifiers

PMID41350288
PMCPMC12783722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.